Med. Pro Praxi 2009; 6(6): 325-329

Adverse effects of anti-tumour treatment and their medication

MUDr. Zdeněk Mechl, CSc1, MUDr. Dagmar, Brančíková2
1 Klinika ORL a chirurgie hlavy a krku, FN u sv. Anny v Brně
2 Komplexní onkologické centrum FN u sv. Anny, Brno

Drug toxicity, along with drug resistance, remains one of the most significant barries to the delivery of curative doses of cancer

chemotherapy. Anticancer cytostatic therapy can cause different acute and subacute side effects, that are related to their administration,

mechanism of action, or effects of their metabolites. With increasing survival rates in cancer patiens, the prevention, detection

and treatment of toxicity has become an increasing area of clinical oncology. The most common toxicities of chemotherapeutic agenst

and their therapy are dicussed.

Keywords: drug toxicity, prevention a treatment of toxicity.

Published: January 1, 2010  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Mechl Z, Brančíková D. Adverse effects of anti-tumour treatment and their medication. Med. praxi. 2009;6(6):325-329.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Sternberg CN. Expanding the boundaries of clinical practice: building on experience with targeted therapies. Ann Oncol 2009; 20(Suppl 1): 11-16. Go to original source... Go to PubMed...
    2. Hesketh PJ. Chemotherapy-induced nausea and vomiting. NEJM 2008; 358: 2482-2494. Go to original source... Go to PubMed...
    3. Zásady cytostatické léčby maligních onkologických onemocnění. ČOS, únor 2009.
    4. Guarneri V, Conte PF. Acute and subacute toxicities of medical anticancer treatment. In: Handbook of Cancer Diagnosis and Treatment Evaluation. ESMO 2009; 91-107. Go to original source...
    5. Greil R, Psenak O, Roila. ESMO Guidelines Working Group. Hematopoietic growth factors. ESMO recommendations for the applications. Ann Oncol 2008; 19(Suppl 2): 116-118. Go to original source... Go to PubMed...
    6. Lenz HJJ. Management and preparedness for infusion and hypersensitivity reactions. Oncologist 2007; 12: 601-609. Go to original source... Go to PubMed...
    7. Peterson DE, Bensadoun RJ, Roila F. ESMO Guidelines Working Group. Management of oral and gastrointestinal mucositis. ESMO clinical recommendations. Ann Oncol 2008; 19(Suppl 2): 122-125. Go to original source... Go to PubMed...
    8. Mulcahy N. NCCN 2009: Recommendations on managing skin toxicities with EGFR inhibitors. NCCN 4th Annual Conference, March 20, 2009.
    9. Bernier J, Bonner J, Vermorken JB. Consensus guidelines for the management of radiation dermatitis and coexisting acne-like rash in patiens receiving radiotherapy plus EGFR inhibitors for the treatment of squamous cell carcinoma of the head and neck. Ann Oncol 2008; 19(Suppl 2): 142-149. Go to original source... Go to PubMed...
    10. Floyd J, Mirza I, Sachs B, et al. Hepatotoxicity of chemotherapy. Semin Oncol 2006; 33: 50-67. Go to original source... Go to PubMed...
    11. Grigorescu AC, Martian M. Respiratory problems. In: Handbook of advanced cancer care, ESMO 2006; 87-104.
    12. Greil R, Thődtman R, Roila F. ESMO Guidelines Working Group. Erytropeoietins in cancer patient. ESMO recommendations for use. Ann Oncol 2008; 190(Suppl 2): 1165-1118. Go to original source... Go to PubMed...

    Return to the content


    Medicine for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.